Drugs in the medical treatment of Cushing's syndrome

Bibliography

• Schteingart DE. Cushing's Syndrome. In: Becker KL, editor, Principles and Practice of Endocrinology and Metabolism. Lippincott Williams and Wilkins publisher. 3rd edition. Chapter 75; 2001. p. 723-38
   Google Scholar
• Schteingart DE. Neoplasms of the adrenal cortex. In: Holland and Frei, editors, Cancer Medicine. BC Decker Inc publisher. 7th edition. Chapter 77; 2006. p. 1103-8
   Google Scholar
• Sonino N, Boscaro M, Mantero F. Prolonged treatment of Cushing's disease by ketoconazole. J Clin Endocrinol Metab 1985;61:718-22
   PubMed Web of Science ®Google Scholar
• Castinetti F, Morange I, Jaquet P, Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. Eur J Endocrinol 2008;158:91-9
   PubMed Web of Science ®Google Scholar
• Engelhardt D, Jacob K, Doerr HG. Different therapeutic efficacy of ketoconazole in patients with Cushing's syndrome. J Mol Med 1989;67:241-7
   Google Scholar
• Abdeen A, McCarty, C, Fluconazole is as effective as ketoconazole in controlling hypercortisolism. Endocr Abstr 2007;13:67
   Google Scholar
• Riedl M, Maier C, Zettinig G, Long-term control of hypercortisolism with fluconazole: case report and in vitro studies. Eur J Endocrinol 2006;154:519-24
   PubMed Web of Science ®Google Scholar
• Schteingart DE, Cash R, Conn JW. Aminoglutethimide and metastatic adrenal cancer. Maintained reversal (six months) of Cushing's syndrome. JAMA 1966;198:1007-10
   PubMed Web of Science ®Google Scholar
• Schteingart D, Conn JW. Effects of aminoglutethimide upon adrenal function and cortisol metabolism in Cushing's syndrome. J Clin Endocrinol Metab 1967;27:1657-66
   PubMed Web of Science ®Google Scholar
• Misbin RI, Canary J, Willard D. Aminoglutethimide in the treatment of Cushing's syndrome. J Clin Pharmacol 1976;16:645-51
   PubMed Web of Science ®Google Scholar
• Jeffcoate WJ, Rees LH, Tomlin S, Metyrapone in long-term management of Cushing's disease. Br Med J 1977;2(6081):215-17
   PubMed Web of Science ®Google Scholar
• Donckier J, Burrin JM, Ramsay ID, Joplin GF. Successful control of Cushing's disease in the elderly with long-term metyrapone. Postgrad Med J 1986;62:727-30
   PubMed Web of Science ®Google Scholar
• Thoren M, Adamson U, Sjoberg HE. Aminoglutethimide and metyrapone in the management of Cushing's syndrome. Acta Endocrinol 1985;109:451-7
   PubMedGoogle Scholar
• Orth DN. Metyrapone is useful only as adjunctive therapy in Cushing's disease. Editorial. Ann Intern Med 1978;89:128-30
   PubMed Web of Science ®Google Scholar
• Schteingart DE, Tsao HS, Taylor CI, Sustained remission of Cushing's disease with mitotane and pituitary irradiation. Ann Intern Med 1980;92:613-19
   PubMed Web of Science ®Google Scholar
• Cai W, Counsell RE, Djanegara T, Metabolic activation and binding of mitotane in adrenal cortex homogenates. J Pharm Sci 1995;84:134-8
   PubMed Web of Science ®Google Scholar
• Schteingart DE. Adjuvant therapy of adrenal cancer-Use and controversy. N Engl J Med 2007;356:2415-18
   PubMed Web of Science ®Google Scholar
• Schteingart DE, Sinsheimer JE, Counsell RE, Comparison of adrenalytic activity of mitotane and a methylated homolog on normal adrenal cortex and adrenal cortical carcinoma. Cancer Chemother Pharmacol 1993;31:459-66
   PubMed Web of Science ®Google Scholar
• Schulte HM, Benker G, Reinwein D, Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab 1990;70:1426-30
   PubMed Web of Science ®Google Scholar
• Drake WM, Perry LA, Hinds CJ, Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing Syndrome and peritonitis. J Clin Endocrinol Metab 1998;83:3542-44
   PubMed Web of Science ®Google Scholar
• Greening JE, Brain CE, Perry LA, Efficient short-term control of hypercortisolaemia by low-dose etomidate in severe paediatric Cushing's disease. Horm Res 2005;64:140-3
   PubMed Web of Science ®Google Scholar
• Komanicky P, Spark RF, Melby JC. Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis. J Clin Endocrinol Metab 1978;47:1042-51
   PubMed Web of Science ®Google Scholar
• Dewis P, Anderson DC, Bullock DE, Experience with trilostane in the treatment of Cushing's syndrome. Clin Endocrinol 1983;18:533-40
   PubMed Web of Science ®Google Scholar
• Krieger DT, Amorosa L, Linick F. Cyproheptadine-induced remission of Cushing's disease. N Engl J Med 1975;293:893-6
   PubMed Web of Science ®Google Scholar
• Miyoshi T, Otsuka F, Takeda M, Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma. J Endocrinol Invest 2004;27:1055-9
   PubMed Web of Science ®Google Scholar
• Pivonello R, DeMartino MC, Faggiano A, Cabergoline treatment in Cushing's disease: effect on hypertension, glucose intolerance and dyslipidemia. Endocr Abstr 2007;14:P558
   Google Scholar
• Casulari LA, Naves LA, Mello PA, Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Horm Res 2004;62:300-5
   PubMed Web of Science ®Google Scholar
• de Bruin C, Pereira AM, Feelders RA, Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin Endocrinol Metab 2009;94:1118-24
   PubMed Web of Science ®Google Scholar
• De Herder WW, Lamberts SWJ. Octapeptide somatostatin-analogue therapy of Cushing's syndrome. Editorial. Postgrad Med J 2005;352:2457-8
   Google Scholar
• Boscaro M, Ludlam WH, Atkinson B, Treatment of pituitary-ACTH dependent Cushing's disease with a multireceptor ligand somatostatin analog pasireotide (SOM 230). A multicenter, phase II trial. J Clin Endocrinol Metab 2009;94:115-22
   PubMed Web of Science ®Google Scholar
• Filosso PL, Rena O, Ruffini E, Oliaro A. Ectopic ACTH-producing tumors of chest and octrotide scintigraphy. Eur J Cardiothorac Surg 2002;21:1126
   PubMed Web of Science ®Google Scholar
• Nolan LA, Schmid HA, Levy A. Octreotide and the novel multireceptor ligand somatostatin receptor agonist pasireotide (SOM230) block the adrenalectomy-induced increase in mitotic activity in male rat anterior pituitary. Endocrinology 2007;148:2821-7
   PubMed Web of Science ®Google Scholar
• Mercado-Asis LB, Yanovski JA, Tracer JL, Acute effects of bromocriptine, cyproheptadine, and valproic acid on plasma adrenocorticotropin secretion in nelson's syndrome. J Clin Endocrinol Metab 1997;82:514-7
   PubMed Web of Science ®Google Scholar
• B Ambrosi, C Dall'Asta, S Cannavo, Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. Eur J Endocrinol 2004;151:173-8
   PubMed Web of Science ®Google Scholar
• Pecori Girardi F, Scaroni C, Arvat E, Effect of protracted treatment with rosiglitazone, a PPARγ agonist, in patients with Cushing's disease. Clin Endocrinol 2006;64:219-24
   PubMed Web of Science ®Google Scholar
• Suri D, Weiss RE. Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease. J Clin Endocrinol Metab 2005;90:1340-6
   PubMed Web of Science ®Google Scholar
• Mullan KR, Leslie H, McCance DR, The PPAR-gamma activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson's syndrome. Clin Endocrinol 2006;64:519-22
   PubMed Web of Science ®Google Scholar
• Libe R, Groussin L, Assie G, Aberrant receptors (AR) in adrenal Cushing's syndrome. Endocr Abstr 2009;20:S23.2
   Google Scholar
• Reznik Y, Allali-Zerah V, Chayvialle JA, Food-dependent Cushing's syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. N Engl J Med 1992;327:981-6
   PubMed Web of Science ®Google Scholar
• Lacroix A, Tremblay J, Rousseau G, Propranolol therapy for ectopic β-adrenergic receptors in adrenal Cushing's syndrome. N Engl J Med 1997;337:1429-34
   PubMed Web of Science ®Google Scholar
• Lacroix A, Tremblay J, Touyz RM, Abnormal adrenal and vascular responses to vasopressin mediated by a V1-vasopressin receptor in a patient with adrenocorticotropin-independent macronodular adrenal hyperplasia, Cushing's syndrome, and orthostatic hypotension. J Clin Endocrinol Metab 1997;82:2414-22
   PubMed Web of Science ®Google Scholar
• Lacroix A, Hamet P, Boutin JM. Leuprolide acetate therapy in luteinizing hormone–dependent Cushing's syndrome. N Engl J Med 1999;341:1577-81
   PubMed Web of Science ®Google Scholar
• Lampron A, Bourdeau I, Oble S, Regulation of aldosterone secretion by several aberrant receptors including for glucose-dependent insulinotropic peptide in a patient with an aldosteronoma. J Clin Endocrinol Metab 2009;94:750-6
   PubMed Web of Science ®Google Scholar
• Castinetti F, Fassnacht M, Johanssen S, Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol 2009;160:1003-10
   PubMed Web of Science ®Google Scholar
• Pivonello R, Ferone D, Lamberts SWJ, Colao A. Cabergoline plus lanreotide for ectopic Cushing's syndrome. N Engl J Med 2005;352:2457-8
   PubMed Web of Science ®Google Scholar